Holen Sie sich die Stockscreener-App
2.715
0.13%
0.005
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ESPR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$2.72
Offen:
$2.67
24-Stunden-Volumen:
4.56M
Relative Volume:
0.69
Marktkapitalisierung:
$551.44M
Einnahmen:
$116.33M
Nettoeinkommen (Verlust:
$-209.25M
KGV:
-1.2807
EPS:
-2.12
Netto-Cashflow:
$-135.49M
1W Leistung:
-11.86%
1M Leistung:
-4.10%
6M Leistung:
+172.60%
1J Leistung:
+30.31%
1-Tages-Spanne:
$2.55
$2.74
1-Wochen-Bereich:
$2.30
$2.745
52-Wochen-Spanne:
$0.6925
$3.94
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Firmenname
Esperion Therapeutics Inc
Sektor
Telefon
734-887-3903
Adresse
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Vergleichen Sie ESPR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
2.735 | 586.01M | 116.33M | -209.25M | -135.49M | -2.12 |
|
ZTS
Zoetis Inc
|
143.48 | 63.05B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.79 | 43.33B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.18 | 40.43B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.14 | 22.97B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
433.24 | 19.90B | 3.08B | 1.24B | 1.07B | 25.61 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-18 | Eingeleitet | Goldman | Neutral |
| 2024-12-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-06-20 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-08-01 | Hochstufung | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | Hochstufung | BofA Securities | Underperform → Buy |
| 2023-03-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-03-16 | Herabstufung | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | Fortgesetzt | BofA Securities | Neutral |
| 2023-02-24 | Hochstufung | Jefferies | Hold → Buy |
| 2023-02-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-03-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-19 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | Herabstufung | Stifel | Buy → Hold |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-11 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-02-12 | Herabstufung | Jefferies | Buy → Hold |
| 2021-02-09 | Herabstufung | Goldman | Neutral → Sell |
| 2021-01-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-11-10 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | Fortgesetzt | JP Morgan | Underweight |
| 2020-08-11 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-03-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-24 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-09-16 | Hochstufung | Goldman | Sell → Neutral |
| 2019-05-29 | Herabstufung | Goldman | Neutral → Sell |
| 2019-05-06 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | Hochstufung | Goldman | Sell → Neutral |
| 2019-03-13 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-07 | Bestätigt | Needham | Strong Buy |
| 2018-12-13 | Eingeleitet | Goldman | Sell |
| 2018-10-29 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | Eingeleitet | BTIG Research | Buy |
| 2018-08-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-07-11 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-05-02 | Herabstufung | BofA/Merrill | Buy → Underperform |
Alle ansehen
Esperion Therapeutics Inc Aktie (ESPR) Neueste Nachrichten
Esperion Therapeutics Inc. stock momentum explainedJuly 2025 Short Interest & Low Risk Growth Stock Ideas - newser.com
Why Esperion Therapeutics Inc. is moving todayMarket Volume Summary & Low Risk Profit Maximizing Plans - newser.com
Will Esperion Therapeutics Inc. stock gain from lower inflation2025 Trading Volume Trends & Safe Entry Momentum Stock Tips - newser.com
Why analysts remain bullish on Esperion Therapeutics Inc. stockQuarterly Profit Report & Fast Entry and Exit Trade Plans - newser.com
Published on: 2025-10-13 11:11:10 - newser.com
What analysts say about MarketAxess Holdings Inc stockMarket Liquidity Analysis & Rapid Portfolio Expansion - earlytimes.in
Published on: 2025-10-13 10:12:04 - newser.com
Published on: 2025-10-13 10:10:18 - newser.com
What’s the recovery path for long term holders of Esperion Therapeutics Inc.Treasury Yields & Weekly Market Pulse Updates - newser.com
Can Esperion Therapeutics Inc. stock reach $100 price targetEarnings Beat & AI Enhanced Trading Signals - newser.com
Why Esperion Therapeutics Inc. stock is favored by top institutions2025 Short Interest & Daily Profit Focused Screening - newser.com
How to use a screener to detect Esperion Therapeutics Inc. breakoutsWeekly Market Report & Long Hold Capital Preservation Tips - newser.com
How strong is Esperion Therapeutics Inc. stock balance sheet2025 Institutional Moves & Fast Exit and Entry Strategy Plans - newser.com
Esperion Therapeutics Inc. (ESPR) Stock Price | Live Quotes & Charts | NSD - StocksToTrade
Esperion Therapeutics (ESPR): Assessing Valuation After $75 Million Discounted Stock Offering and Share Price Drop - Yahoo Finance
Will Esperion Therapeutics Inc. stock benefit from upcoming earnings reportsJuly 2025 Fed Impact & Advanced Technical Analysis Signals - newser.com
Why Esperion Therapeutics (ESPR) Is Up After $75M Equity Raise and Generic Settlement News - Yahoo Finance
How currency fluctuations impact Esperion Therapeutics Inc. stockTake Profit & Fast Momentum Entry Tips - newser.com
Why Is Esperion Therapeutics Stock Sinking Premarket Today? - Stocktwits
Is Esperion Therapeutics Inc. stock attractive for hedge fundsJuly 2025 Selloffs & Safe Entry Point Identification - newser.com
ESPR- Japanese Drug Approval, Otsuka Payments to Help this Biotech Play - Yahoo Finance
(10/10/25) ESPR: Japanese Drug Approval, Otsuka Payments to Help this Biote - moneyshow.com
ESPR Stock Drops 17% on Pricing of $75M Common Stock Offering - sharewise.com
Is Esperion Therapeutics Inc. stock a buy on dips2025 Trading Volume Trends & Safe Entry Trade Reports - newser.com
Published on: 2025-10-09 02:49:28 - newser.com
Esperion Therapeutics (NASDAQ:ESPR) Earns Sell (D-) Rating from Weiss Ratings - MarketBeat
Esperion Announces Public Offering to Raise $70.2 Million - TipRanks
Esperion Therapeutics Down Over 15%, on Pace for Largest Percent Decrease Since December 2024 -- Data Talk - 富途牛牛
Esperion Therapeutics (NASDAQ:ESPR) Shares Gap DownShould You Sell? - MarketBeat
Esperion Therapeutics’ Bold Move: Stock Offering at $2.50 - StocksToTrade
Esperion Therapeutics prices $75M public offering - MSN
Penguin Solutions Posts Q4 Earnings, Joins Esperion Therapeutics, Joby Aviation And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Esperion Therapeutics Prices $75 Million Share Offering - MarketScreener
Esperion prices $75 million public offering of common stock By Investing.com - Investing.com Nigeria
Esperion Announces Pricing of Public Offering of Common Stock - The Manila Times
Esperion prices public offering of 30 million shares at $2.50 each - MarketScreener
Esperion Therapeutics Announces Pricing of $75 Million Public Offering of Common Stock - Quiver Quantitative
Esperion prices $75 million public offering of common stock - Investing.com India
$75M Raise — Esperion Prices 30M Shares to Fund Oral LDL‑C Program - Stock Titan
Esperion Therapeutics Experiences Evaluation Revision Amidst Mixed Market Indicators and Performance Trends - Markets Mojo
Esperion announces proposed public offering of common stock - MarketScreener
ESPR Settles Nexletol/Nexlizet Patent Litigation With RDY, Stock Up - MSN
Esperion launches public offering of common stock to raise capital By Investing.com - Investing.com Canada
Esperion Therapeutics tumbles after stock offering launch - TradingView
Esperion Announces Strategic Expansion Plans for Bempedoic Acid - TipRanks
Esperion launches public offering of common stock to raise capital - Investing.com
Finanzdaten der Esperion Therapeutics Inc-Aktie (ESPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.02%
2.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):